Clinical Trial Update: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial evaluating an HLA-A*2402 restricted peptide vaccine for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HLA-A*2402 restricted peptide vaccine

Snippet

Sponsor: Tokyo University | Conditions: Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN